Would you prefer nivolumab/ipilimumab combination over single agent pembrolizumab for a metachronous low volume MSI-H, metastatic colon cancer, with KRAS mutation?

To date, I don't think there are any single negative or positive predictive markers of response to immunotherapy in dMMR/MSI-High.

The ones identified retrospectively on subset analyses include

• KRAS as you mentioned
• Other studies with BRAF,
• Or liver metastatic disease
• Elderly

However, my take/experi...